Headline
The latest stories from AHA Today.
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention guidance.
Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969 hospitalized adults with COVID-19 pneumonia in the United States, Japan, Mexico, Singapore and South Korea, the National Institutes of Health…
The Health Resources and Services Administration Oct. 21 will host the last in a series of webinar sessions on how to apply for a portion of $25.5 billion in COVID-19 relief funds.
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19 pediatric hospitals released by the Centers for Disease Control and Prevention.
The AHA urged the Centers for Medicare & Medicaid Services to conduct the necessary oversight and enforcement of the No Surprises Act to ensure patients benefit from these new protections and to prevent widespread, negative consequences of any misapplication of the policy.
Nearly three-fourths of the 2.4 million U.S. adults who reported using buprenorphine in 2019 did not misuse the medication in the past 12 months, according to a National Institutes of Health study released in JAMA Network Open.
The Food and Drug Administration approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases.
A symposium hosted by the AHA at the HLTH conference featured a panel of experts discussing health transformation in the post-pandemic world.
The AHA urged the Centers for Medicare & Medicaid Services to revise and reissue recent proposed regulations streamlining prior authorization requirements within certain coverage programs; consider additional regulations to limit care delays; and conduct oversight and enforcement for plans who…
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during COVID-19.